๐๏ธ Verified NIH Record โข Updated 2026-01-09
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer (NCT05156866)
A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced Cancer
๐ต Active, Not Recruiting Phase1 ๐ Investigational Drug / Biologic Sponsor: TORL Biotherapeutics, LLC
๐ฉบ Plain-English Summary (8th-Grade Level)
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
Who can join: Review the eligibility criteria below.
Location: Providence St. Jude Medical Center โ Fullerton, California
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (12 Sites)
- Providence St. Jude Medical Center โ Fullerton, California
- UCLA - JCCC Clinical Research Unit โ Los Angeles, California
- Torrance Memorial Medical โ Torrance, California
- Fort Wayne Medical Oncology and Hematology โ Fort Wayne, Indiana
- Washington University School of Medicine-Siteman Cancer Center โ St Louis, Missouri
- Texas Oncology-Austin โ Austin, Texas
- Texas Oncology-Dallas โ Dallas, Texas
- START San Antonio โ San Antonio, Texas
- Texas Oncology-Tyler โ Tyler, Texas
- Seoul National University Hospital โ Seoul,
- Severance Hospital, Yonsei University Health System โ Seoul,
- Seoul National University Bundang Hospital โ Seoul,
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression โ Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors โ Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations โ Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors โ Houston, Texas
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors โ San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.